Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14492-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- HBXIP antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated HBXIP antibody (Cat. #14492-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Germacrone Regulates HBXIP-Mediated Cell Cycle, Apoptosis and Promotes the Formation of Autophagosomes to Inhibit the Proliferation of Gastric Cancer Cells.
HBXIP: a potential prognosis biomarker of colorectal cancer which promotes invasion and migration via epithelial-mesenchymal transition.
Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells.
HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma.
HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.
The oncoprotein hepatitis B X-interacting protein promotes the migration of ovarian cancer cells through the upregulation of S-phase kinase-associated protein 2 by Sp1.
The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells.
The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
Fang X, Tan T, Gao B, Zhao Y, Liu T, Xia Q
Frontiers in oncology 2020;10:537322
Frontiers in oncology 2020;10:537322
HBXIP: a potential prognosis biomarker of colorectal cancer which promotes invasion and migration via epithelial-mesenchymal transition.
Wang X, Feng Q, Yu H, Zhou X, Shan C, Zhang Q, Liu S
Life sciences 2020 Mar 15;245:117354
Life sciences 2020 Mar 15;245:117354
Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells.
Wang L, Liu M, Yin F, Wang Y, Li X, Wu Y, Ye C, Liu J
Molecules (Basel, Switzerland) 2019 Sep 18;24(18)
Molecules (Basel, Switzerland) 2019 Sep 18;24(18)
HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Zhou X, Wang X, Duan J, Sun W, Chen Z, Li Q, Ou Z, Jiang G, Ren X, Liu S
Pathology, research and practice 2019 Feb;215(2):343-346
Pathology, research and practice 2019 Feb;215(2):343-346
Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma.
Xia H, Ma L, Li J, Bai H, Wang D
American journal of cancer research 2017;7(11):2190-2198
American journal of cancer research 2017;7(11):2190-2198
HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
Wang Y, Li N, Che S, Jin T, Piao J, Liu S, Lin Z
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Jul;39(7):1010428317709675
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Jul;39(7):1010428317709675
HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.
Wang Y, Sun J, Li N, Che S, Jin T, Liu S, Lin Z
Journal of ovarian research 2017 Apr 7;10(1):26
Journal of ovarian research 2017 Apr 7;10(1):26
The oncoprotein hepatitis B X-interacting protein promotes the migration of ovarian cancer cells through the upregulation of S-phase kinase-associated protein 2 by Sp1.
Xu F, Zhu X, Han T, You X, Liu F, Ye L, Zhang X, Wang X, Yao Y
International journal of oncology 2014 Jul;45(1):255-63
International journal of oncology 2014 Jul;45(1):255-63
The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells.
Xu F, You X, Liu F, Shen X, Yao Y, Ye L, Zhang X
Cancer letters 2013 Jun 1;333(1):124-32
Cancer letters 2013 Jun 1;333(1):124-32
The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You X, Lin Z, Zhang X, Ye L
The Journal of biological chemistry 2012 Aug 31;287(36):30228-39
The Journal of biological chemistry 2012 Aug 31;287(36):30228-39
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Transfected HEK-293 cells were subjected to SDS PAGE followed by western blot with 14492-1-AP( HBXIP Antibody) at dilution of 1:800
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 14492-1-AP(HBXIP antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The HBXIP antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human HBXIP. This antibody recognizes human,mouse,rat antigen. The HBXIP antibody has been validated for the following applications: ELISA, IHC, WB analysis.
